Tettero Jesse M, Freeman Sylvie, Buecklein Veit, Venditti Adriano, Maurillo Luca, Kern Wolfgang, Walter Roland B, Wood Brent L, Roumier Christophe, Philippé Jan, Denys Barbara, Jorgensen Jeffrey L, Bene Marie C, Lacombe Francis, Plesa Adriana, Guzman Monica L, Wierzbowska Agnieszka, Czyz Anna, Ngai Lok Lam, Schwarzer Adrian, Bachas Costa, Cloos Jacqueline, Subklewe Marion, Fuering-Buske Michaela, Buccisano Francesco
Department of Hematology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
Department of Clinical Immunology, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, United Kingdom.
Hemasphere. 2021 Dec 22;6(1):e676. doi: 10.1097/HS9.0000000000000676. eCollection 2022 Jan.
Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts from the MRD Working Party of the European LeukemiaNet evaluated which aspects are crucial for accurate MFC-MRD measurement. Here, we report on the agreement, obtained via a combination of a cross-sectional questionnaire, live discussions, and a Delphi poll. The recommendations consist of several key issues from bone marrow sampling to final laboratory reporting to ensure quality and reproducibility of results. Furthermore, the experiences were tested by comparing two 8-color MRD panels in multiple laboratories. The results presented here underscore the feasibility and the utility of a harmonized theoretical and practical MFC-MRD assessment and are a next step toward further harmonization.
通过多参数流式细胞术（MFC）定量的可测量残留病（MRD）是急性髓系白血病（AML）中一个强大且独立的预后因素。然而，一些技术因素可能会影响该检测的最终结果解读。欧洲白血病网MRD工作组的专家评估了哪些方面对于准确的MFC-MRD测量至关重要。在此，我们报告通过横断面问卷调查、现场讨论和德尔菲法相结合所达成的共识。这些建议涵盖了从骨髓采样到最终实验室报告的几个关键问题，以确保结果的质量和可重复性。此外，通过在多个实验室比较两个8色MRD检测板对这些经验进行了验证。此处呈现的结果强调了统一的理论和实践MFC-MRD评估的可行性和实用性，是朝着进一步统一迈出的下一步。
